FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 191 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation MOST POPULAR ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... March 10, 2023 FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer April 14, 2021 How Living in Service to Others Helped Me Cope During Cancer March 9, 2023 ¿Cómo están cambiando los requisitos de elegibilidad para los ensayos clínicos... March 16, 2023 Load more HOT NEWS Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless... Utility of Prospective ctDNA Surveillance in Early TNBC and the Activity... Stopping TKI Treatment Is Safe, Improves Quality of Life for Some... Scientists uncover how incurable skin cancer resists treatment at the end...
